Reimbursement Review Reports


( Last Updated : May 25, 2022)

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Actemra Tocilizumab Arthritis, polyarticular juvenile idiopathic List with criteria/condition Complete
Actemra Tocilizumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete
Actemra Tocilizumab Arthritis, rheumatoid List with criteria/condition Complete
Actemra tocilizumab Giant cell arteritis (GCA) Reimburse with clinical criteria and/or conditions Complete
Actikerall Fluorouracil and Salicylic Acid Hyperkeratotic actinic keratosis Reimburse with clinical criteria and/or conditions Complete
Adcirca Tadalafil Pulmonary arterial hypertension List with clinical criteria and/or conditions Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Withdrawn
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder, Adult Do not list Complete
Adempas Riociguat Chronic thromboembolic pulmonary hypertension List with criteria/condition Complete